This study aims to thoroughly investigate the impact of the HER2-L755S mutation and its drug-binding efficiency on four drugs: lapatinib (drug-resistant) and afatinib, neratinib, and ibrutinib (drug-sensitive) for BC. Here, ERBB2 is linked to breast cancer.